Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07734636 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Prompt REstart Study of Renin-Angiotensin System Inhibitors After Acute Kidney Injury

Study acronym: APRES-AKI
StatusRecruiting
PhasePhase 4
Started2026-09-01
View on ClinicalTrials.gov ↗

Amendment history

2026-09-04
Study Status, Contacts/Locations v1
Recruitment opened
Start dateestimated 2026-08→confirmed 2026-09-01
Study sitesdetails revised at 1 of 1 site
2026-07-23
Original filing
The goal of this pilot clinical trial is to learn if early restart of renin-angiotensin system inhibitor (RASi) medications is feasible and well-tolerated in hospitalized patients with acute kidney injury (AKI). Researchers will compare early RASi restart to usual care. Study participants will restart RASi per study protocol, obtain a lab test in 1-2 weeks if RASi restarted in the hospital and not collected as part of routine care, and answer questions at the 90-day follow-up.
Trial Details
NCT Number NCT07734636
Lead Sponsor University of California, San Francisco
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions Acute Kidney Injury
Enrollment 60 participants
Start Date 2026-09-01
Primary Completion 2029-03 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-09-08